Jardiance (empagliflozin) 25 mg tablets are being recalled due to a labeling mix-up. Approximately 69,375 bottles, which includes both 30-count and 90-count sizes, are affected by this action. Jardiance is a prescription medication used to treat type 2 diabetes. Consumers should speak with their pharmacist or healthcare provider to determine if their medication is part of the recall.
A labeling mix-up can lead to incorrect dosing or patient confusion if the information on the bottle does not accurately describe the tablets inside. No injuries or adverse incidents have been reported in relation to this recall.
You have 2 options:
Recall number D-0468-2023; Rx only medication.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.